In a phase I study, Gilead Sciences' PI3K-δ inhibitor idelalisib produced rapid tumor shrinkage-a response that lasted for 17 months on average-in about half of the 54 patients with chronic lymphocytic leukemia who participated.
In a phase I study , Gilead Sciences ' PI3K - δ inhibitor idelalisib produced rapid tumor shrinkage - a response that lasted for 17 months on average - in about half of the 54 patients with chronic lymphocytic leukemia who participated .
What is the target protein of the drug Idelalisib?
What is the target protein of the drug Idelalisib ?
PI3K-δ
PI3K-δ phosphoinositol-3 kinase delta isoform